Abstract
Central serous chorioretinopathy (CSCR) is a retinal disorder characterized by subretinal fluid (SRF) accumulation, and its bullous variant represents a rare and severe form often lacking standardized treatment. We report a case of a patient with short stature and normal cortisol and growth hormone levels, diagnosed with the bullous variant of CSCR and treated with oral spironolactone, a mineralocorticoid receptor (MR) antagonist. The patient showed marked resolution of exudative retinal detachment (RD) and improvement in visual acuity within one month of initiating therapy with 50 mg/day of spironolactone. This case highlights the potential role of oral spironolactone as an effective and less invasive therapeutic option for managing the bullous variant of CSCR, offering a promising alternative to more aggressive interventions.